Correlated Stock Forecasts

Assets that tend to move strongly with BMY



JNJ Forecast + Options Trading Strategies   [JNJ]  Johnson & Johnson (0.77)


PRU Forecast + Options Trading Strategies   [PRU]  Prudential Financial (0.63)


PTEN Forecast + Options Trading Strategies   [PTEN]  Patterson-UTI Energy (0.62)


IBM Forecast + Options Trading Strategies   [IBM]  International Business Machines (0.62)


STZ Forecast + Options Trading Strategies   [STZ]  Constellation Brands (0.62)



Uncorrelated Stock Forecasts

Assets with little price relationship to BMY



AMBA Forecast + Options Trading Strategies   [AMBA]  Ambarella (-0.0)


JKS Forecast + Options Trading Strategies   [JKS]  JinkoSolar (0.01)


CRM Forecast + Options Trading Strategies   [CRM]  Salesforce.Com (0.02)


VMW Forecast + Options Trading Strategies   [VMW]  Vmware (-0.04)


ZG Forecast + Options Trading Strategies   [ZG]  Zillow (0.04)



Anticorrelated Stock Forecasts

Assets that tend to move strongly against BMY



AYX Forecast + Options Trading Strategies   [AYX]  Alteryx (-0.3)


RBLX Forecast + Options Trading Strategies   [RBLX]  Roblox Corporation - (-0.3)


PINS Forecast + Options Trading Strategies   [PINS]  Pinterest (-0.37)


DUOL Forecast + Options Trading Strategies   [DUOL]  Duolingo (-0.47)


FLNC Forecast + Options Trading Strategies   [FLNC]  Fluence Energy (-0.49)


BMY News over Time





Click points to explore news by date. News sentiment ranges from -10 (very negative) to +10 (very positive) where 0 is neutral.

Most Recent BMY News

















BMY Helium News Summary: Bristol-Myers Squibb has announced a $0.57 dividend and is developing Avadomide hydrochloride for follicular lymphoma.

Meanwhile, Giovanni Caforio has sold 240,000 shares in the company, while the company's short percent of float has fallen significantly.

Investors are also keen on Bristol-Myers Squibb's cash position and its promising 2022 earnings.

A report by Brainy Insights highlights Bristol-Myers Squibb's contribution to the pruritus therapeutics market, while Nasdaq includes BMY in its list of top analyst reports.

Overall, Bristol-Myers Squibb remains a leading global healthcare company with multiple projects and presence in different sectors of the medical industry.